Breaking News

Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences

Expands its portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry.

Author Image

By: Charlie Sternberg

Associate Editor

Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from Coherus BioSciences Inc. UDENYCA, a biosimilar to Neulasta (pegfilgrastim), expands the company’s portfolio of FDA-approved products and accelerates Accord BioPharma’s growth in the biosimilar industry. By acquiring UDENYCA, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, will continue to make this treatment available to decrease the incidence of infecti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters